{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:07:48Z","timestamp":1789164468802,"version":"build-2803163510"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T00:00:00Z","timestamp":1530835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Genocea Biosciences Inc."},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>GEN-003 is a candidate therapeutic vaccine for genital herpes simplex virus type 2 (HSV-2). We compared virologic and clinical impact of varying GEN-003 doses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adults with symptomatic HSV-2 received placebo or GEN-003 (30 or 60 \u00b5g antigen with 25, 50, or 75 \u00b5g adjuvant). Viral shedding and lesion rates before vaccination were compared with those measured immediately after vaccination, then at weeks 29\u201333 and 53\u201357 after last dose.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Compared with baseline shedding rates, the rate ratios for viral shedding immediately after treatment were as follows: 0.82 (95% confidence interval [CI], 0.49\u20131.36), 30 \u00b5g antigen\/25 \u00b5g adjuvant (30\/25) dose; 0.64 (95% CI, 0.45\u20130.92), 30\/50 dose; 0.63 (95% CI, 0.37\u20131.10), 30\/75 dose; 0.56 (95% CI, 0.36\u20130.88), 60\/25 dose; 0.58 (95% CI, 0.38\u20130.89), 60\/50 dose; 0.45 (95% CI, 0.16\u20130.79), 60\/75 dose; and 0.98 (95% CI, 0.76\u20131.26), placebo. Lesion rate reductions by GEN-003 ranged from 31% to 69%, but lesion rates also decreased among placebo recipients (62%). Reductions in shedding and lesion rate were durable for 12 months for the 60 \u00b5g antigen plus 50 or 75 \u00b5g adjuvant groups. No serious adverse events occurred with vaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The most efficacious vaccine combinations for GEN-003 were the 60 \u00b5g\/50 \u00b5g and 60 \u00b5g\/75 \u00b5g doses.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiy415","type":"journal-article","created":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T02:59:45Z","timestamp":1530673185000},"page":"1890-1899","source":"Crossref","is-referenced-by-count":45,"title":["Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital Herpes Simplex Virus-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-Controlled Trial"],"prefix":"10.1093","volume":"218","author":[{"given":"Nicholas","family":"Van Wagoner","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Fife","sequence":"first","affiliation":[{"name":"Department of Medicine, Indiana University, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A","family":"Leone","sequence":"first","affiliation":[{"name":"Department of Medicine, University of North Carolina, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I","family":"Bernstein","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Cincinnati Children\u2019s Hospital, Cincinnati"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Warren","sequence":"first","affiliation":[{"name":"Westover Heights Clinic, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Panther","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Beth Israel Deaconess Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M","family":"Novak","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, University of Illinois, Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Beigi","sequence":"first","affiliation":[{"name":"Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Pittsburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kriesel","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Tyring","sequence":"first","affiliation":[{"name":"Center for Clinical Studies, University of Texas Health Science Center; Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Koltun","sequence":"first","affiliation":[{"name":"Medical Center for Clinical Research, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg","family":"Lucksinger","sequence":"first","affiliation":[{"name":"Tekton Research, Austin, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Morris","sequence":"first","affiliation":[{"name":"IND 2 Results, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"first","affiliation":[{"name":"Genocea Biosciences, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K","family":"McNeil","sequence":"first","affiliation":[{"name":"Genocea Biosciences, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybil","family":"Tasker","sequence":"first","affiliation":[{"name":"Genocea Biosciences, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Hetherington","sequence":"first","affiliation":[{"name":"Genocea Biosciences, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wald","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington Fred Hutchinson Cancer Research Center, Seattle, Washington"},{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,7,6]]},"reference":[{"key":"2020043006260503200_CIT0001","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1056\/NEJMcp1603178","article-title":"Genital herpes","volume":"375","author":"Gnann","year":"2016","journal-title":"N Engl J Med"},{"key":"2020043006260503200_CIT0002","doi-asserted-by":"crossref","first-page":"e114989","DOI":"10.1371\/journal.pone.0114989","article-title":"Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012","volume":"10","author":"Looker","year":"2015","journal-title":"PLoS One"},{"key":"2020043006260503200_CIT0003","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2015","volume":"64","author":"Workowski","year":"2015","journal-title":"MMWR Recomm Rep"},{"key":"2020043006260503200_CIT0004","doi-asserted-by":"crossref","first-page":"847","DOI":"10.7326\/0003-4819-121-11-199412010-00004","article-title":"Recurrence rates in genital herpes after symptomatic first-episode infection","volume":"121","author":"Benedetti","year":"1994","journal-title":"Ann Intern Med"},{"key":"2020043006260503200_CIT0005","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1086\/424519","article-title":"Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract","volume":"190","author":"Gupta","year":"2004","journal-title":"J Infect Dis"},{"key":"2020043006260503200_CIT0006","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(11)61750-9","article-title":"Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials","volume":"379","author":"Johnston","year":"2012","journal-title":"Lancet"},{"key":"2020043006260503200_CIT0007","first-page":"39","article-title":"Suppressive valacyclovir therapy to reduce genital herpes transmission: good public health policy","volume":"12","author":"Bonnar","year":"2009","journal-title":"McGill J Med"},{"key":"2020043006260503200_CIT0008","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/sti.2007.027631","article-title":"In search of optimal genital herpes management and standard of care (INSIGHTS): doctors\u2019 and patients\u2019 perceptions of genital herpes","volume":"84","author":"Romanowski","year":"2008","journal-title":"Sex Transm Infect"},{"key":"2020043006260503200_CIT0009","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1016\/j.vaccine.2016.09.001","article-title":"Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1\/2a trial","volume":"34","author":"Flechtner","year":"2016","journal-title":"Vaccine"},{"key":"2020043006260503200_CIT0010","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/infdis\/jix004","article-title":"Therapeutic vaccine for genital herpes simplex virus-2 infection: findings from a randomized trial","volume":"215","author":"Bernstein","year":"2017","journal-title":"J Infect Dis"},{"key":"2020043006260503200_CIT0011","author":"Food and Drug Administration","year":"2007"},{"key":"2020043006260503200_CIT0012","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1128\/JVI.02745-12","article-title":"An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs","volume":"87","author":"Skoberne","year":"2013","journal-title":"J Virol"},{"key":"2020043006260503200_CIT0013","author":"FAMVIR (famciclovir)","year":"2011"},{"key":"2020043006260503200_CIT0014","author":"VALTREX (valacyclovir hydrochloride)","year":"2008"},{"key":"2020043006260503200_CIT0015","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.1172\/JCI57148","article-title":"HSV-2: in pursuit of a vaccine","volume":"121","author":"Johnston","year":"2011","journal-title":"J Clin Invest"},{"key":"2020043006260503200_CIT0016","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/archinte.168.11.1137","article-title":"The treatment of herpes simplex infections: an evidence-based review","volume":"168","author":"Cernik","year":"2008","journal-title":"Arch Intern Med"},{"key":"2020043006260503200_CIT0017","article-title":"Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development","author":"Schiffer","year":"2017","journal-title":"Vaccine"},{"key":"2020043006260503200_CIT0018","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/1359105310367528","article-title":"The psychological impact of genital herpes stigma","volume":"16","author":"Merin","year":"2011","journal-title":"J Health Psychol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/218\/12\/1890\/33147066\/jiy415.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/218\/12\/1890\/33147066\/jiy415.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T11:09:42Z","timestamp":1588244982000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/218\/12\/1890\/5049813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,6]]},"references-count":18,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,7,6]]},"published-print":{"date-parts":[[2018,11,5]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiy415","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,12,15]]},"published":{"date-parts":[[2018,7,6]]}}}